Hope For Non-Hallucinogenic Neuroplastogens [Drug Discovery Online]
Monday, March 9, 2026 1 min read
Key Takeaway: Enveric Biosciences is working on non-hallucinogenic neuroplastogens as a safer alternative to psychedelics. These compounds aim to maintain therapeutic neuroplasticity signaling while minimizing the risk of hallucinations. CEO Joseph Tucker discusses the potential benefits of this innovative approach in drug development.
Price reaction · baseline $1.895 (2026-03-09T13:52:00.000Z) · hit during market hours · clean, no other ENVB news in the window
day 0 close · peak
+5%
day 1
+4.5%
day 3
+1.3%
Market Sentiment Analysis
POSITIVE FACTORS
Development of non-hallucinogenic neuroplastogens offers safer alternatives.
Potential to preserve therapeutic neuroplasticity signaling.
Lower risk of hallucinations compared to traditional psychedelics.
Full Press Release Details
A conversation with Joseph Tucker, Ph.D., CEO, Enveric Biosciences
Non-hallucinogenic neuroplastogens are being developed as a potentially safer alternative to psychedelics, with a lower risk of hallucinations. Enveric Biosciences is developing a derivative designed to preserve signaling associated with therapeutic neuroplasticity while potentially reducing hallucinogenic risk.
Full Article >>
Frequently Asked Questions
What are non-hallucinogenic neuroplastogens?
They are compounds being developed as safer alternatives to psychedelics, reducing hallucination risks.
Who is leading the development of these neuroplastogens?
Joseph Tucker, Ph.D., is the CEO of Enveric Biosciences, overseeing the development.
What is the goal of these neuroplastogens?
The aim is to preserve therapeutic neuroplasticity signaling while minimizing hallucinogenic effects.